NCT06514755 Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain
| NCT ID | NCT06514755 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zagazig University |
| Condition | Chronic Knee Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-09-29 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-09-29 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether performing genicular nerve ablation (GNA) before geniculate artery embolization (GAE) improves pain relief and knee function in patients with chronic knee pain. The main questions it aims to answer are: * Does performing GNA prior to GAE enhance pain relief, as measured by the Visual Analog Scale (VAS), at 3 months post-procedure? * Does the sequential approach improve knee function as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)? Study investigators will compare two groups to see if the sequential approach (GNA followed by GAE) provides better outcomes compared to GAE alone. Participants will: * Undergo either sequential GNA followed by GAE or GAE alone * Have their knee pain and function assessed at baseline, 1 month, 3 months, and 6 months post-procedure * Complete a structured patient satisfaction questionnaire (PSQ) at 3 months post-procedure * Be monitored for procedure-related adverse events up to 6 months post-procedure,
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 80 years. * Diagnosed with chronic knee pain refractory to conservative treatment. * Able to provide informed consent. * Agree to follow the study procedures and attend follow-up visits. Exclusion Criteria: * Contraindications to GNA or GAE procedures (e.g., allergy to local anesthetics, active infection at the procedure site). * Recent knee surgery within the last six months. * Severe comorbid conditions that may interfere with the study outcomes (e.g., rheumatoid arthritis, other severe autoimmune diseases). * Current participation in another clinical trial that could interfere with the outcomes of this study.
Contact & Investigator
Ahmed A Bessar, MD, PhD
PRINCIPAL INVESTIGATOR
Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.
Frequently Asked Questions
Who can join the NCT06514755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Chronic Knee Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06514755 currently recruiting?
Yes, NCT06514755 is actively recruiting participants. Contact the research team at Ahmedawadbessar@gmail.com for enrollment information.
Where is the NCT06514755 trial being conducted?
This trial is being conducted at Zagazig, Egypt.
Who is sponsoring the NCT06514755 clinical trial?
NCT06514755 is sponsored by Zagazig University. The principal investigator is Ahmed A Bessar, MD, PhD at Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.. The trial plans to enroll 60 participants.